Semax comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
== M == MAC – macrophage – macrophage-tropic virus – magnetic resonance imaging (MRI) – MAI – maintenance therapy – major histocompatibility complex (MHC) – malabsorption syndrome – malaise – malignant – mast cell – MedlinePlus – mega-HAART – memory T cells – meninges – meningitis – messenger RNA – metabolism – metastasis – MHC – microbes – microbicide – Microsporidiosis – mitochondria – mitochondrial toxicity – molecule – molluscum contagiosum – monocyte – mononeuritis multiplex (MM) – monovalent vaccine – morbidity – MRI – mucocutaneous – mucosa – mucosal immunity – mucous membrane – Multicenter AIDS Cohort Study – multi-drug rescue therapy – multiple drug-resistant tuberculosis (MDR-TB) – mutation – myalgia – mycobacterium – mycobacterium avium complex (MAC) – mycosis – myelin – myelopathy – myelosuppression – myelotoxic – myocardial – myopathy
Antiprion drugs Antiretroviral drug (especially HAART for HIV) COVID-19 drug repurposing research CRISPR-Cas13 Discovery and development of CCR5 receptor antagonists (for HIV) Discovery and development of NS5A inhibitors List of antiviral drugs Monoclonal antibody
=== Pseudomonas syringae pv. tomato strain DC3000 and Arabidopsis thaliana === As mentioned above, the genome of P. syringae pv. tomato DC3000 has been sequenced, and approximately 40 Hop (Hrp Outer Protein) effectors - pathogenic proteins that attenuate the host cell - have been identified. These 40 effectors are not recognized by A. thaliana thus making P. syringae pv. tomato DC3000 virulent against it - that is, P. syringae pv. tomato DC3000 is able to infect A. thaliana - thus A. thaliana is susceptible to this pathogen. Many gene-for-gene relationships have been identified using the two model organisms, P. syringae pv. tomato strain DC3000 and Arabidopsis. The gene-for-gene relationship describes the recognition of pathogenic avirulence (avr) genes by host resistance genes (R-genes). P. syringae pv. tomato DC3000 is a useful tool for studying avr: R-gene interactions in A. thaliana because it can be transformed with avr genes from other bacterial pathogens, and furthermore, because none of the endogenous hops genes is recognized by A. thaliana, any observed avr recognition identified using this model can be attributed to recognition of the introduced avr by A. thaliana. The transformation of P. syringae pv. tomato DC3000 with effectors from other pathogens have led to the identification of many R-genes in Arabidopsis to further advance knowledge of plant pathogen interactions.
(People with HIV/AIDS or hepatitis C are usually excluded from this requirement.) In practice, 40–65% of patients maintain abstinence from additional opioids while receiving opioid replacement therapy and 70–95% can reduce their use significantly. Medical (improper diluents, non-sterile injecting equipment), psychosocial (mental health, relationships), and legal (arrest and imprisonment) issues that can arise from the use of illegal opioids are concurrently eliminated or reduced. Clonidine or lofexidine can help treat the symptoms of withdrawal. The period when initiating methadone and the time immediately after discontinuing treatment with both drugs are periods of particularly increased mortality risk, which should be dealt with by both public health and clinical strategies. ORT has proved to be the most effective treatment for improving the health and living condition of people experiencing illegal opiate use or dependence, including mortality reduction and overall societal costs, such as the economic loss from drug-related crime and healthcare expenditure. A review of UK hospital policies found that local guidelines delayed access to substitute opioids, for instance by requiring lab tests to demonstrate recent use or input from specialist drug teams before prescribing. Delays to access can increase people's risk of discharging themselves early against medical advice.
== Adverse effects == The most common side effects of pivekimab sunirine include swelling (edema), tiredness (fatigue), muscle and joint pain (musculoskeletal pain), bleeding (hemorrhage), infusion-related reactions, nausea, diarrhea, changes in kidney function tests (increased creatinine), low albumin levels, and changes in liver function tests (transaminases increased). The US prescribing information includes a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease, and warnings and precautions for infusion-related reactions, edema, sulfite allergic reactions, and embryo-fetal toxicity. Pivekimab sunirine may cause a severe form of liver damage (hepatotoxicity) called veno-occlusive disease (blockage of small blood vessels that makes it hard for blood to leave the liver, leading to backup and swelling), including severe or fatal hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome). Pivekimab sunirine may cause a serious side effect called infusion-related reaction, which may be life-threatening or lead to death if not treated. Pivekimab sunirine contains sulfite and may cause severe, life-threatening allergic reactions in some people. Pivekimab sunirine may cause severe fluid retention and harm to an unborn baby.
Sources: en.wikipedia.org
The 2026 Israel–Lebanon ceasefire is a cessation of hostilities agreed between Israel and Lebanon on 16 April 2026, amid the ongoing 2026 Lebanon war and wider regional conflict linked to the 2026 Iran war. The agreement, brokered by the United States, established a 10-day truce intended to halt active fighting and create conditions for further negotiations toward a longer-term settlement. The ceasefire came into effect shortly after its announcement and marked the first direct diplomatic engagement between Israel and Lebanon in decades. On 17 April, Iran announced that passage of commercial vessels through the Hormuz Strait was completely open during the truce in Lebanon, but closed it again the next day in response to the US refusal to lift its naval blockade. On 23 April, US President Donald Trump announced that Israel and Lebanon agreed to a three-week extension of the ceasefire. On 27 April, Hezbollah leader Naim Qassem stated that the group will not revert to the pre-March status and will respond to Israeli attacks. On 15 May, the truce was extended for another 45 days. On 1 June, Israel and Hezbollah agreed to a ceasefire, with Israel committing not to target Beirut's southern suburbs and Hezbollah vowing not to attack Israel, under a US proposal aiming to extend the ceasefire to all of Lebanon. On 3 June, Israel and Lebanon agreed to renew the ceasefire, mediated by the US, and plan to establish "pilot zones".
=== Defensive behavior === The primary defense strategy performed by P. phalangioides in moments of predation is whirling. Whirling, or a gyration of the body, consists of the spider swinging its body around in a circle repeatedly while its legs remain fixed on the web. This whirling strategy is induced as soon as the individual recognizes any sort of movement occurring in its web. The duration of this whirling is related to the specific kind of predator that the spider encounters. Short-duration whirling can be induced simply by a human touching the spider's web or occasionally by spider of a different species. Long-duration whirling, which can last several hours or even days, is performed specifically in response to the presence of the more threatening Salticid, or jumping spiders, much more often than for spiders of other families. The rapid gyrating associated with the whirling disturbs the vision of the Salticid spiders such that they can no longer rely on their acute eyesight to pinpoint the location of P. phalangioides. This disruption results in the safety of the spiders from an otherwise deadly predator.
=== Flavodoxin-1 domain === Flavoproteins are ubiquitous biocatalysts binding specific redox active prosthetic groups. The domain is associated with electron transfer proteins and used in electron transport systems. The cofactor flavin-mononucleotide (FMN) is bound non-covalently to the domain, which is functionally interchangeable with iron-sulfur constituted proteins regulating electron transfer or ferredoxins.
In the summer of 1793 the sans-culottes, the Parisian enragés especially, accused even the most radical Jacobins of being too tolerant of greed and insufficiently universalist. From this far-left point of view, all Jacobins were at fault because all of them tolerated existing civil life and social structures. The sans-culottes also populated the ranks of paramilitary forces charged with physically enforcing the policies and legislation of the revolutionary government, a task that commonly included violence and the carrying out of executions against perceived enemies of the revolution. During the peak of their influence, the sans-culottes were seen as the truest and most authentic sons of the French Revolution, held up as living representations of the revolutionary spirit. During the height of revolutionary fervor, such as during the Reign of Terror when it was dangerous to be associated with anything counter-revolutionary, even public functionaries and officials actually from middle or upper-class backgrounds adopted the clothing and label of the sans-culottes as a demonstration of solidarity with the working class and patriotism for the new French Republic. But by early 1794, as the bourgeois and middle-class elements of the revolution began to gain more political influence, the fervent working-class radicalism of the sans-culottes rapidly began falling out of favour within the National Convention.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.